SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary 础叠叠滨贰鈩� platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.
The 础叠叠滨贰鈩� platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.
SOHM, Inc. (OTC:SHMN) ha sviluppato con successo una linea cellulare di cancro ovarico geneticamente modificata (SKOV3) che sovraesprime il gene GYS1 utilizzando la loro piattaforma proprietaria 础叠叠滨贰鈩�. Questa innovazione rappresenta uno strumento prezioso per il screening di inibitori di GYS1, poich茅 GYS1 猫 un enzima fondamentale nel metabolismo energetico cellulare, collegato alla sopravvivenza delle cellule tumorali. La linea cellulare ingegnerizzata, SKOV3-GYS1+, offre un sistema pronto all'uso per valutare composti mirati a GYS1, particolarmente rilevante per tumori aggressivi come quelli ovarici, mammari e pancreatici.
La piattaforma 础叠叠滨贰鈩� consente un editing genico ad alta specificit脿 senza l'uso di vettori virali, e SOHM prevede di ampliare il proprio portafoglio di linee cellulari ingegnerizzate per bersagli metabolici e di immuno-oncologia nel corso del 2025.
SOHM, Inc. (OTC:SHMN) ha desarrollado con 茅xito una l铆nea celular de c谩ncer de ovario modificada gen茅ticamente (SKOV3) que sobreexpresa el gen GYS1 utilizando su plataforma patentada 础叠叠滨贰鈩�. Este avance proporciona una herramienta valiosa para la detecci贸n de inhibidores de GYS1, ya que GYS1 es una enzima crucial en el metabolismo energ茅tico celular relacionada con la supervivencia de las c茅lulas cancerosas. La l铆nea celular modificada, SKOV3-GYS1+, ofrece un sistema listo para usar para evaluar compuestos dirigidos a GYS1, especialmente relevante para c谩nceres agresivos como los de ovario, mama y p谩ncreas.
La plataforma 础叠叠滨贰鈩� permite una edici贸n gen茅tica de alta especificidad sin vectores virales, y SOHM planea ampliar su cartera de l铆neas celulares modificadas para objetivos metab贸licos e inmunooncol贸gicos durante 2025.
SOHM, Inc. (OTC:SHMN)電� 霃呾瀽鞝侅澑 础叠叠滨贰鈩� 頂岆灚韽�鞚� 靷毄頃橃棳 GYS1 鞙犾爠鞛�毳� 瓿茧皽順勴晿電� 鞙犾爠鞛� 氤�順� 雮滌唽鞎� 靹疙彫欤�(SKOV3)毳� 靹标车鞝侅溂搿� 臧滊皽頄堨姷雼堧嫟. 鞚� 須嶊赴鞝侅澑 靹标臣電� GYS1鞚� 鞎旍劯韽� 靸濎〈瓿� 甏�霠悳 靹疙彫 鞐愲剤歆� 雽�靷棎靹� 欷戩殧頃� 須唽鞛勳潉 臧愳晥頃� 霑�, GYS1 鞏奠牅鞝� 鞀ろ伂毽嫕鞐� 毵れ毎 鞙犾毄頃� 霃勱惮毳� 鞝滉车頃╇媹雼�. 臧滊皽霅� 靹疙彫欤� SKOV3-GYS1+電� 雮滌唽鞎�, 鞙犽癌鞎�, 旆岇灔鞎旉臣 臧欖潃 瓿店博鞝侅澑 鞎旍棎 韸鬼瀳 鞝來暕頃� GYS1 響滌爜 頇旐暕氍� 韽夑皜鞐� 歃夓嫓 靷毄頃� 靾� 鞛堧姅 鞁滌姢韰滌潉 鞝滉车頃╇媹雼�.
础叠叠滨贰鈩� 頂岆灚韽检潃 氚旍澊霟姢 氩№劙 鞐嗢澊 雴掛潃 韸轨澊靹膘潣 鞙犾爠鞛� 韼胳鞚� 臧�電ロ晿瓴� 頃橂┌, SOHM鞚� 2025雲勱箤歆� 雽�靷� 氚� 氅挫棴頃晹 響滌爜鞚� 鞙勴暅 鞙犾爠鞛� 氤�順� 靹疙彫欤� 韽姼韽措Μ鞓るゼ 頇曥灔頃� 瓿勴殟鞛呺媹雼�.
SOHM, Inc. (OTC:SHMN) a d茅velopp茅 avec succ猫s une lign茅e cellulaire de cancer de l'ovaire g茅n茅tiquement modifi茅e (SKOV3) surexprimant le g猫ne GYS1 gr芒ce 脿 leur plateforme propri茅taire 础叠叠滨贰鈩�. Cette avanc茅e constitue un outil pr茅cieux pour le criblage des inhibiteurs de GYS1, car GYS1 est une enzyme cl茅 du m茅tabolisme 茅nerg茅tique cellulaire li茅e 脿 la survie des cellules canc茅reuses. La lign茅e cellulaire modifi茅e, SKOV3-GYS1+, offre un syst猫me pr锚t 脿 l'emploi pour 茅valuer des compos茅s ciblant GYS1, particuli猫rement pertinent pour les cancers agressifs tels que ceux de l'ovaire, du sein et du pancr茅as.
La plateforme 础叠叠滨贰鈩� permet une 茅dition g茅n茅tique 脿 haute sp茅cificit茅 sans vecteurs viraux, et SOHM pr茅voit d'茅largir son portefeuille de lign茅es cellulaires modifi茅es pour des cibles m茅taboliques et en immuno-oncologie tout au long de 2025.
SOHM, Inc. (OTC:SHMN) hat erfolgreich eine genetisch ver盲nderte Eierstockkrebs-Zelllinie (SKOV3) entwickelt, die das GYS1-Gen mithilfe ihrer propriet盲ren 础叠叠滨贰鈩�-Plattform 眉berexprimiert. Dieser Durchbruch bietet ein wertvolles Werkzeug zum Screening von GYS1-Inhibitoren, da GYS1 ein entscheidendes Enzym im zellul盲ren Energiestoffwechsel ist, das mit dem 脺berleben von Krebszellen verbunden ist. Die entwickelte Zelllinie SKOV3-GYS1+ stellt ein gebrauchsfertiges System zur Bewertung von GYS1-gerichteten Verbindungen dar, was besonders f眉r aggressive Krebsarten wie Eierstock-, Brust- und Bauchspeicheldr眉senkrebs relevant ist.
Die 础叠叠滨贰鈩�-Plattform erm枚glicht eine hochspezifische Genbearbeitung ohne virale Vektoren, und SOHM plant, sein Portfolio an genetisch ver盲nderten Zelllinien f眉r metabolische und immunonkologische Zielstrukturen im Laufe des Jahres 2025 zu erweitern.
- Development of novel SKOV3-GYS1+ cell line enables rapid screening of GYS1 inhibitors
- 础叠叠滨贰鈩� platform demonstrates capability for high-efficiency gene editing with low off-target effects
- Company plans portfolio expansion into metabolic and immuno-oncology targets in 2025
- None.
CHINO HILLS, CALIFORNIA / / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development of a genetically modified ovarian cancer cell line (SKOV3) overexpressing the GYS1 gene, using its proprietary gene editing platform, 础叠叠滨贰鈩�. This breakthrough establishes a powerful tool for the rapid screening of novel glycogen synthase 1 (GYS1) inhibitors and underscores SOHM's capacity to swiftly generate custom-engineered cell models to support targeted drug development.
GYS1 (glycogen synthase 1) is a pivotal enzyme in cellular energy metabolism, with emerging evidence linking its overexpression to cancer cell survival and immune evasion under metabolic stress. Elevated GYS1 activity has been implicated in tumor adaptation to nutrient-poor environments-particularly in aggressive cancers such as ovarian, breast, and pancreatic malignancies-making it an attractive and underexplored therapeutic target.
"Our new SKOV3-GYS1+ cell line represents a versatile, ready-to-use system for biotech and pharma partners looking to evaluate GYS1-targeted compounds," said Dr. David Aguilar, SOHM's COO. "This is just one example of how 础叠叠滨贰鈩� enables the rapid and precise engineering of human cell models to match emerging research priorities."
The 础叠叠滨贰鈩� gene editing platform is designed for high specificity and fast turnaround, enabling SOHM to customize cell lines across a range of oncology and rare disease applications. 础叠叠滨贰鈩� delivers high efficiency with low off-target effects, streamlining the development of disease-relevant screening models without the need for viral vectors.
SOHM plans to expand its engineered cell line portfolio to include other metabolic and immuno-oncology targets in 2025, aiming to empower early-stage drug developers with physiologically relevant models for high-throughput compound screening.
About SOHM, Inc.
SOHM is a US-based pharmaceutical and biotechnology company focused on developing and manufacturing cutting-edge therapeutic solutions, including cell and gene therapies, to address unmet medical needs globally. With the 础叠叠滨贰鈩� gene editing platform, SOHM is unlocking a new era of customized disease models to support drug discovery, from bench to bedside.
Safe Harbor Statement
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
Media Contact:
SOHM, Inc.
714-522-6700
[email protected]
SOURCE: SOHM, Inc
View the original on ACCESS Newswire
FAQ
What is the significance of SOHM's new GYS1 ovarian cancer cell line?
How does SHMN's ABBIE platform work in gene editing?
What are SOHM's (SHMN) plans for cell line development in 2025?
Why is GYS1 an important target for cancer treatment?
